2026-04-28T21:22:11Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/689882025-09-11T06:24:13Zcom_10324_69224com_10324_954com_10324_894com_10324_40357com_10324_952com_10324_1138com_10324_931col_10324_69227col_10324_40358col_10324_1226

Impact of COVID-19 confinement on quality of life of patients with age-related macular degeneration: a two-wave panel study Sanabria Ruiz Colmenares, María Rosa Calles Monar, Paola Stefanía Alonso Tarancón, Ana María Coco Martín, Rosa María Mayo Iscar, Agustín Producción Científica ABSTRACT: Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. Intravitreal injections of antiangiogenic agents (anti-VEGF) can stop vision loss in the neovascular form of the disease (nAMD). The aim of this study was to assess the general healthrelated quality of life (HRQoL) in a cohort of patients with nAMD treated with intravitreal anti-VEGF injections and to detesrmine to what extent their HRQoL was affected by COVID-19. This was an observational, analytical, and longitudinal study performed with a two-wave panel survey. Clinical outcomes, HRQoL, and tangible support were evaluated. In the final survey, changes in living conditions and medical visits due to the COVID-19 pandemic were also examined. Of the 102 patients initially interviewed in the before-COVID survey, 24 were lost after 30 months of follow-up. In the initial assessment, the mean health index was 0.73 0.2. The EQ VAS score worsened at the final survey (p = 0.048). Patients needing treatment in both eyes (p = 0.007) and with lower levels of bilateral visual acuity (p = 0.018) reported an increase in social support at the final survey. In conclusion, patients perceived a worsening in HRQoL after confinement. However, patients enjoyed good social support that improved in the after-COVID survey. 2024-07-22T18:04:23Z 2024-07-22T18:04:23Z 2023 info:eu-repo/semantics/article J Clin Med, 20 Mar 2023, vol. 12, n. 6, Article number: 2394, 15 páginas. 2077-0383 https://uvadoc.uva.es/handle/10324/68988 10.3390/jcm12062394 1 6 15 Journal of Clinical Medicine 12 2077-0383 eng https://www.mdpi.com/2077-0383/12/6/2394 info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-nd/4.0/ MDPI Attribution-NonCommercial-NoDerivatives 4.0 Internacional MDPI SI